In this video, Donald J. D’Amico, MD, discusses data from the phase 1/2 PRISM trial of 4D-150 in patients with neovascular age-related macular degeneration.
The study, presented at the ASRS annual meeting in Stockholm, evaluated the safety of the investigational intravitreal gene therapy from 4D Molecular Therapeutics in 32 patients with follow-up ranging from 8 to 16 weeks.
Although robust efficacy data for this compound do not exist yet, D’Amico emphasized the safety data.
“It’s encouraging that there were no alarming safety signals,” D’Amico, professor and